Publications by authors named "Trembleau C"
Article Synopsis
- - The study aims to improve treatment for microsatellite stable rectal cancer, which typically shows poor T cell infiltration and doesn't respond well to existing immune therapies like checkpoint inhibitors.
- - Researchers are testing a new approach that combines short-course radiotherapy with the immunotherapy drug pembrolizumab in a clinical trial involving 25 patients, who will receive both treatments prior to surgery.
- - This trial includes a comprehensive analysis of tumor and blood samples to assess the biological effects of the combined treatment, marking it as the first of its kind in rectal cancer.
A better understanding of the molecular deregulation leading to carcinogenesis allows the development of numerous novel targeted therapeutic candidates. Clinical research in oncology is a critical step to evaluate in a thorough manner the safety and efficacy of these innovative compounds. During the last four years the fruitful partnership between the Geneva University Hospitals and the Dr.
View Article and Find Full Text PDFBackground: A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC).
Patients And Methods: CRC patients not pretreated with palliative chemotherapy, with performance status < or =1 and adequate haematological, kidney and liver function, were eligible. Treatment consisted in weekly 24-h infusion 5-FU (2300 mg/m(2))/LV (30 mg) and alternating OHP (70-85 mg/m(2), days 1 and 15) and CPT-11 (80-140 mg/m(2), days 8 and 22) repeated every 5 weeks.